Korea Investment CORP Makes New Investment in Abbott Laboratories $ABT

Korea Investment CORP purchased a new position in Abbott Laboratories (NYSE:ABT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 877,413 shares of the healthcare product maker’s stock, valued at approximately $79,616,000.

Other large investors have also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter worth approximately $25,000. Cornerstone Financial Management LLC bought a new stake in Abbott Laboratories in the 4th quarter valued at about $25,000. Purpose Unlimited Inc. acquired a new position in Abbott Laboratories during the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories in the 4th quarter worth about $26,000. Finally, Abound Financial LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $26,000. Institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the subject of several recent analyst reports. Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. JPMorgan Chase & Co. upped their target price on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. The Goldman Sachs Group lowered their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. Bank of America dropped their price objective on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Finally, UBS Group cut their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $119.50.

Abbott Laboratories Trading Down 1.8%

NYSE ABT opened at $110.48 on Tuesday. The firm’s 50 day moving average price is $103.06 and its two-hundred day moving average price is $100.13. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The stock has a market cap of $191.17 billion, a price-to-earnings ratio of 35.75, a PEG ratio of 2.18 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.